an immuno-oncologist who was one among other contributors within the field to identify PD-L1 (B7-H1). Nonetheless, the Nobel Prize in 2018 went to James Allison and Tasuku Honjo for this research ...

Responses were observed across a range of B7-HR expression levels, as well as in patients who had received prior treatment with PD-1 or PD-L1 inhibitors. The median progression-free survival was 7 ...

While CTLA-4, PD-1, and PD-L1 are the primary focus of current ICIs, there are several other immune regulatory molecules that scientists are investigating as potential future targets for ICI therapies ...

Tecentriq is a monoclonal antibody designed to bind with PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.